An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study. Researchers at Flinders University and the University of South Australia ...

Relief for men experiencing the challenges of Benign Prostatic Hyperplasia (BPH), or prostate enlargement, has arrived with the introduction of Flowel and Flowel Plus by Superior Pharmaceuticals ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Prostate Cancer - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering. This "Prostate Cancer - Competitive landscape ...

A prostate cancer study that could change how doctors treat some patients found that widely used hormone-blocking drugs did not improve survival chances for older men whose disease hadn't spread. In ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Prostate Cancer Drugs Market was valued at US$ 13.22 billion in 2024 and is projected to reach US$ 28.10 billion by 2033, growing at a CAGR of 8.1 percent ...